Signant Health, Lothar Medical sign LOI to bring ALDS PRO respiratory assessment system to clinical trials

• Signant Health signed a letter of intent with Lothar Medical to develop an integrated respiratory-trial data offering.
• Planned product would combine TrialMax eCOA with Lothar Medical’s ALDS PRO pulmonary assessment system for use in global clinical trials.
• Signant is expected to become the exclusive provider of ALDS PRO for drug-trial applications under the planned commercialization framework.
• ALDS PRO consolidates spirometry, oscillometry, FeNO in one portable device, targeting simpler site workflows, training, equipment management.
• Partnership is positioned to support sensor-enhanced eCOA by linking patient-reported outcomes with objective respiratory measures in studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Signant Health published the original content used to generate this news brief on September 05, 2026, and is solely responsible for the information contained therein.